Arthur T Knackerbracket has found the following story:
A simple arthritis drug could be an effective, low cost solution to treat patients with blood cancers such as polycythemia vera (PV) and essential thrombocythemia (ET), a breakthrough study by the University of Sheffield has shown.
Led by Dr Martin Zeidler, from the University of Sheffield's Department of Biomedical Science and Dr Sebastian Francis from the Department of Haematology at the Royal Hallamshire Hospital, as well as the Universities of Oxford and Cambridge, the study results show that methotrexate (MTX) -- a drug on the World Health Organisation list of essential medicines that is commonly used to treat rheumatoid arthritis -- significantly reduces the symptoms associated with the disease.
[...] Building on previous Medical Research Council-funded work in the Zeidler lab that identified methotrexate as an inhibitor of the JAK/STAT signalling pathway, this study examined hospital records to identify existing ET and PV patients already taking methotrexate for other diseases.
Despite the small numbers involved and the presence of background rheumatoid arthritis, these patients reported significantly lower symptom scores than patients not taking methotrexate.
The misregulation of the JAK/STAT signalling pathway in humans is central to the development of Myeloproliferative neoplasms (MPNs), the collective term for progressive blood cancers like ET and PV and is also central to many inflammatory processes such as those associated with rheumatoid arthritis.
Lab-based results showed that low doses of methotrexate acted as a powerful suppressor of JAK/STAT pathway activation -- even in cells carrying the mutated gene responsible for MPNs in patients.
Dr Zeidler said: "While we still need to undertake a clinical trial to validate these findings, our results are very encouraging and suggest that a simple drug that has been used for nearly 40 years to treat arthritis can provide significant relief to blood cancer sufferers.
"Patients we tested showed a pronounced improvement in symptoms, something conventional treatments have been unable to provide.
"Given the very low cost of MTX, this research could offer an effective therapy on a budget accessible to healthcare systems throughout the world -- marking a potentially substantial clinical and health economic benefit."
[...] The results of the study have today (17 September 2019) been published in the British Journal of Haematology.
(Score: 3, Touché) by fustakrakich on Thursday September 19 2019, @07:01AM (4 children)
Now they're going to raise the price by 20,000%
La politica e i criminali sono la stessa cosa..
(Score: 2) by FatPhil on Thursday September 19 2019, @09:00AM
Great minds discuss ideas; average minds discuss events; small minds discuss people; the smallest discuss themselves
(Score: 2) by esperto123 on Thursday September 19 2019, @12:10PM (2 children)
The saddest thing is that this is probably true.
Current pharma companies would increase price of aspirin 1000 fold if it was discovered it helped cure any cancer and say that this is to cover the costs of developing the drug with a completely straight face.
(Score: 1, Interesting) by Anonymous Coward on Thursday September 19 2019, @12:33PM
The most likely tactic is to blend it with something else and patent the result as a miracle cancer cure. Then quietly take the old drug off the market by making it hard to find.
Kind of like insulin.
The FDA and patent office should set up a honey pot on this one.
It will be interesting to see what happens to this active ingredient over time.
(Score: 0) by Anonymous Coward on Saturday September 21 2019, @06:45AM
Don't forget: methotrexate has been - and still is - prescribed for treating certain kinds of cancer since 1947: https://en.wikipedia.org/wiki/Methotrexate#History [wikipedia.org].
This drug is a chemotherapeutic agent, and is both used as monotherapy (that is: the sole drug for treating cancer), as well as in combination therapy (happy mix of toxic compounds). MTX is still widely used for treatment of leukemia, lymphoma and certain bone cancers, AFAIK. In case of active cancer treatment, people either get an IV or take pills daily.
In case of arthritis, people mostly get pills, and low dosages (somewhere between 10-30mg per week). At those levels, side effects are - relatively speaking - mild: fatigue, vomiting and overall having a crappy defense against the flu.